Deer-sourced brewer's yeast strain I017, microbial agent containing the same and application thereof

By developing the Saccharomyces cerevisiae strain I017 in the deer, the problem of insufficient research on the intestinal microorganisms of sika deer is solved, and a microbial resource suitable as a probiotic additive is provided, which significantly improves the growth performance of sika deer and is safely colonized in the intestines of animals. , achieves the regulation of intestinal health.

CN118620754BActive Publication Date: 2024-11-05HEBEI HUAREN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411097913.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-05
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

In the prior art, the research on the intestinal microorganisms of sika deer is relatively limited, especially the isolation and identification of yeasts are rarely reported, resulting in the lack of special animal microorganism resources suitable as probiotic additives.

Method used

Deer-sourced Saccharomyces cerevisiae strain I017 has developed a good tolerance, in vitro secretion of amylase and lipase, degradation of triglycerides and removal of cholesterol, and is used to prepare feeding probiotic products that promote the growth of sika deer. and feed additives that regulate animal intestinal flora.

Benefits of technology

This strain has a high survival rate in artificial gastric juice and intestinal fluid, can adapt to the bile salt environment, has significant antioxidant ability and antibacterial effect, significantly improves the weight gain effect of sika deer antler, and is safely colonized in the intestines of animals without affecting the animals. health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118620754B_ABST
    Figure CN118620754B_ABST
Patent Text Reader

Abstract

The present invention provides a deer-derived saccharomyces cerevisiae strain I017, a microbial agent containing the same, and an application thereof, and relates to the field of functional microbial technology. The deer-derived saccharomyces cerevisiae strain I017 has a strong tolerance to artificial gastric juice, can grow and reproduce in artificial intestinal juice, and has good acid resistance, and is a yeast with strong stress resistance; in addition, the saccharomyces cerevisiae strain I017 can secrete amylase and lipase in vitro; has a high in vitro degradation rate of triglycerides, and can also remove part of cholesterol in vitro. Therefore, the strain I017 can be widely used in the preparation of probiotic products for feeding sika deer, functional feed, or the preparation of probiotic products with lipid-lowering effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of functional microorganisms, and in particular to a deer-derived saccharomyces cerevisiae strain I017 containing a microbial agent and applications thereof. Background Art

[0002] In the field of biodiversity research, research on intestinal microbiota is increasing, and intestinal flora plays an important role in maintaining host health, providing nutrition and regulating immune response. Although the intestinal microbial composition of humans and some livestock has been widely studied, the understanding of the intestinal microbiota of special economic animals, especially sika deer, is relatively limited.

[0003] As a ruminant, the digestive system and intestinal microbiota of sika deer may be closely related to its food source, living habits and ecological environment. Changes in intestinal microorganisms can affect animal growth and development, nutrient utilization, immune function and even reproductive performance. Isolating and identifying microorganisms in the intestines of sika deer not only helps to understand the nutritional physiology and health status of sika deer, but also may provide new beneficial microbial resources for ruminants, which can be used in the development of feed additives or other microbial preparations.

[0004] At the same time, yeast plays an important role in maintaining intestinal health, promoting digestion and absorption, and enhancing immune regulation, and its feeding prospects are broad. A large number of studies have isolated yeast from livestock intestines and fermented foods, but there are few reports on the isolation of yeast from sika deer intestines. Since most strains are host-specific, screening and identifying yeast from special animals such as sika deer has positive significance for supplementing the microbial resource library and developing microbial preparations that promote animal growth.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The object of the present invention is to provide a deer-derived saccharomyces cerevisiae strain ( Saccharomyces cerevisiae ) strain I017, which has good tolerance, can secrete amylase and lipase in vitro, degrade triglycerides and remove cholesterol, and can be developed and utilized as a potential probiotic additive.

[0007] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0008] The present invention provides a deer-derived brewer's yeast ( Saccharomyces cerevisiae ) strain I017, deposit number is CCTCC NO: M2024600.

[0009] Furthermore, the physiological and biochemical characteristics of the strain I017 include:

[0010] After being treated in artificial gastric juice for 3 hours, Saccharomyces cerevisiae I017 was able to maintain ≥10 5 The number of viable bacteria in CFU / mL;

[0011] The survival rate of Saccharomyces cerevisiae I017 after being treated with artificial intestinal fluid for 3 hours was greater than 99%;

[0012] Saccharomyces cerevisiae I017 grew well in YPD medium containing 0.3% bile salts;

[0013] Saccharomyces cerevisiae I017 grows well in a culture environment with a pH of 3.0-7.0.

[0014] Furthermore, the biological characteristics of the strain I017 include:

[0015] The scavenging rate of Saccharomyces cerevisiae I017 to 0.20 mmol / L DPPH free radical was 58.96%;

[0016] Saccharomyces cerevisiae I017 can secrete amylase and lipase in vitro;

[0017] Saccharomyces cerevisiae I017 can degrade triglycerides and remove cholesterol in vitro.

[0018] The present invention provides a microbial agent comprising the above-mentioned deer-derived saccharomyces cerevisiae strain I017 and auxiliary materials.

[0019] Furthermore, the microbial agent is a microbial aqueous agent.

[0020] Furthermore, the microbial aqueous solution is a fermentation liquid of deer-derived saccharomyces cerevisiae strain I017.

[0021] Furthermore, the live bacterial concentration of strain I017 in the fermentation liquid of Luyuan Saccharomyces cerevisiae strain I017 is 10 5 ~10 9 CFU / mL.

[0022] The present invention provides an application of the deer-derived saccharomyces cerevisiae strain I017 or the microbial agent in the preparation of a feeding probiotic product for promoting the growth of sika deer antlers.

[0023] The probiotic product for feeding is a fermented bacterial liquid of the deer-derived Saccharomyces cerevisiae strain I017, and the concentration of live bacteria of the strain I017 in the fermented bacterial liquid is 10 5 ~10 9 CFU / mL, preferably 10 7 CFU / mL.

[0024] The feeding method of the probiotics is: on a daily basis, the feeding concentration is 10 per kg body weight.5 ~10 9 10 ml of deer-derived Saccharomyces cerevisiae strain I017 bacterial solution with CFU / mL.

[0025] The present invention provides an application of the deer-derived saccharomyces cerevisiae strain I017 or the microbial agent in the preparation of a feed additive or health-care product for regulating the intestinal flora structure of an animal.

[0026] The present invention provides an application of the deer-derived saccharomyces cerevisiae strain I017 or the microbial agent in the preparation of a probiotic product with lipid-lowering effect.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] The present application studies the biological characteristics of the deer-derived brewer's yeast strain I017 and finds that the bacterium has good tolerance, a high survival rate in artificial gastric juice, sustainable growth and reproduction in artificial intestinal juice, can adapt to a 0.3% bile salt environment, and can proliferate normally under a culture condition of pH 3; the bacterium is sensitive to most antifungal drugs, such as voriconazole, ketoconazole, fluconazole and itraconazole; its fermentation supernatant has a good antibacterial effect on Staphylococcus aureus; the bacterium has a high self-aggregation rate, a relatively low surface hydrophobicity, and good adhesion ability; it has a high DPPH free radical scavenging rate and strong antioxidant capacity; at the same time, the strain can secrete amylase and lipase in vitro; it has a high in vitro degradation rate of triglycerides, and can also remove part of cholesterol in vitro, so it has the potential to lower blood lipids.

[0029] In addition, research has found that the fermentation liquid of the deer-derived brewer's yeast strain I017 of the present application is used as a probiotic product for feeding sika deer. Compared with other yeast or probiotic products, it has no significant effect on the feed intake and body weight of sika deer, but can significantly increase the weight of antlers, and has a significant antler weight-increasing effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0031] Figure 1 This is a morphological characteristic diagram of strain I017 provided in Example 1 of the present invention;

[0032] Figure 2 The growth curve and acid production curve of strain I017 provided in Example 1 of the present invention;

[0033] Figure 3 The phylogenetic tree of strain I017 provided in Example 1 of the present invention;

[0034] Figure 4 This is a graph showing the bile salt tolerance results of Saccharomyces cerevisiae I017 provided in Example 2 of the present invention;

[0035] Figure 5 This is a graph showing the test results of the surface hydrophobicity of Saccharomyces cerevisiae I017 provided in Example 2 of the present invention;

[0036] Figure 6 This is a graph showing the self-aggregation rate test results of Saccharomyces cerevisiae I017 provided in Example 2 of the present invention;

[0037] Figure 7 The growth curve of strain I017 provided in Example 2 of the present invention under different acidic conditions;

[0038] Figure 8 This is a graph showing the inhibitory effect of strain I017 provided in Example 2 of the present invention on Staphylococcus aureus;

[0039] Fig. 9 The amylase hydrolysis circle produced by Saccharomyces cerevisiae I017 provided in Example 2 of the present invention;

[0040] Fig.10 A comparison chart of bile salt hydrolase activity of strain I017 provided in Example 2 of the present invention;

[0041] Fig.11 A graph showing the growth of strain I017 provided in Example 2 of the present invention on a neutral red medium;

[0042] Fig.12 The initial and final weight effects diagram of mice provided in Example 3 of the present invention;

[0043] Fig.13 The mouse growth curve provided in Example 3 of the present invention;

[0044] Fig.14 The final body shape of the mouse provided in Example 3 of the present invention;

[0045] Fig.15 The graph of mouse liver morphology, weight and liver index provided in Example 3 of the present invention;

[0046] Fig.16 The mouse spleen morphology, weight and spleen index diagram provided in Example 3 of the present invention;

[0047] Fig.17 The mouse kidney morphology, weight and kidney index diagram provided in Example 3 of the present invention;

[0048] Fig.18 The graph of mouse intestinal morphology, weight and colon length provided in Example 3 of the present invention;

[0049] Fig.19 This is a graph showing the HE staining results of mouse jejunum tissue provided in Example 3 of the present invention;

[0050] Fig. 20 This is a graph showing the HE staining results of mouse colon tissue provided in Example 3 of the present invention;

[0051] Fig.21 This is a graph showing the levels of ALT and AST in mouse serum provided in Example 3 of the present invention. DETAILED DESCRIPTION

[0052] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0053] According to one aspect of the present invention, a deer-derived Saccharomyces cerevisiae strain I017, wherein the strain I017 has been deposited in the China Center for Type Culture Collection on April 1, 2024, with a deposit number of CCTCCNO: M2024600, a deposit date of April 1, 2024, and a deposit address of No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province.

[0054] It should be noted that the deer-derived Saccharomyces cerevisiae strain I017 is a yeast isolated from the intestinal contents of sika deer. The yeast grows fast and has the function of producing acid. Through the determination and analysis of the strain's morphological characteristics, physiological and biochemical properties and ITSrRNA gene sequence, it was determined that this strain is Saccharomyces cerevisiae and was named Saccharomyces cerevisiae I017.

[0055] The present application studies the biological characteristics of the deer-derived brewer's yeast strain I017 and finds that the bacterium has good tolerance, a high survival rate in artificial gastric juice, sustainable growth and reproduction in artificial intestinal juice, can adapt to a 0.3% bile salt environment, and can proliferate normally under a culture condition of pH 3; the bacterium is sensitive to most antifungal drugs, such as voriconazole, ketoconazole, fluconazole and itraconazole; its fermentation supernatant has a good antibacterial effect on Staphylococcus aureus; the bacterium has a high self-aggregation rate, a relatively low surface hydrophobicity, and good adhesion ability; it has a high DPPH free radical scavenging rate and strong antioxidant capacity; at the same time, the strain can secrete amylase and lipase in vitro; it has a high in vitro degradation rate of triglycerides, and can also remove part of cholesterol in vitro, so it has the potential to lower blood lipids.

[0056] In a preferred embodiment of the present invention, the physiological and biochemical characteristics of the strain I017 include:

[0057] After being treated in artificial gastric juice for 3 hours, Saccharomyces cerevisiae I017 was able to maintain ≥10 5 The number of viable bacteria in CFU / mL;

[0058] The survival rate of Saccharomyces cerevisiae I017 after being treated with artificial intestinal fluid for 3 hours was greater than 99%;

[0059] Saccharomyces cerevisiae I017 grew well in YPD medium containing 0.3% bile salts;

[0060] Saccharomyces cerevisiae I017 grows well in a culture environment with a pH of 3.0-7.0.

[0061] It has been verified through experiments that the brewer's yeast I017 of the present application has good tolerance, a high survival rate in artificial gastric juice, can sustainably grow and reproduce in artificial intestinal juice, can adapt to a 0.3% bile salt environment, and can proliferate normally under culture conditions of pH 3.

[0062] In a preferred embodiment of the present invention, the biological characteristics of the strain I017 include:

[0063] The scavenging rate of Saccharomyces cerevisiae I017 to 0.20 mmol / L DPPH free radical was 58.96%;

[0064] Saccharomyces cerevisiae I017 can secrete amylase and lipase in vitro;

[0065] Saccharomyces cerevisiae I017 can degrade triglycerides and remove cholesterol in vitro.

[0066] Experimental verification has shown that the brewer's yeast I017 of the present application has a high DPPH free radical scavenging rate and strong antioxidant capacity; at the same time, it can secrete amylase and lipase in vitro, has a high in vitro degradation rate of triglycerides, and can also remove part of cholesterol in vitro, so it has the potential to be developed into a lipid-lowering probiotic product.

[0067] According to one aspect of the present invention, a microbial agent comprises the above-mentioned deer-derived Saccharomyces cerevisiae strain I017 and auxiliary materials.

[0068] In a preferred embodiment of the present invention, the microbial agent is a microbial aqueous agent.

[0069] In a preferred embodiment of the present invention, the microbial aqueous solution is a fermentation broth of deer-derived Saccharomyces cerevisiae strain I017.

[0070] In the above preferred embodiment, the live bacteria concentration of strain I017 in the fermentation liquid of deer-derived Saccharomyces cerevisiae strain I017 is 10 5 ~10 9 CFU / mL, preferably 10 7 CFU / mL.

[0071] The present invention provides an application of the deer-derived saccharomyces cerevisiae strain I017 or the microbial agent in the preparation of a feeding probiotic product for promoting the growth of sika deer antlers.

[0072] In a preferred embodiment of the present invention, the probiotic product for feeding is a fermentation broth of deer-derived Saccharomyces cerevisiae strain I017, and the live bacteria concentration of strain I017 in the fermentation broth is 10 5 ~10 9 CFU / mL, preferably 10 7 CFU / mL.

[0073] As a preferred embodiment, the feeding method of the probiotics to the sika deer is: on a daily basis, the feeding concentration is 10 per kg body weight. 5 ~10 9 5~10ml of the bacterial solution of deer-derived Saccharomyces cerevisiae strain I017 with CFU / mL.

[0074] The results of the experiment show that the daily feeding concentration per kg body weight is 1.03×10 9 After the sika deer were fed for 45 days, the average antler weight growth rate was increased by 14.9% compared with the control group not fed with the fermented bacterial solution of the deer-derived saccharomyces cerevisiae strain I017 of the present application, which had a significant antler weight-increasing effect.

[0075] According to one aspect of the present invention, the deer-derived Saccharomyces cerevisiae strain I017 or the microbial agent is used in the preparation of a feed additive or health product for regulating the intestinal flora structure of an animal.

[0076] The deer-derived saccharomyces cerevisiae strain I017 or the microbial agent provided by the present invention can be widely used in preparing feed additives or health products for regulating the intestinal flora structure of animals.

[0077] According to one aspect of the present invention, the deer-derived Saccharomyces cerevisiae strain I017 or the microbial agent is used in the preparation of a probiotic product with lipid-lowering effect.

[0078] The deer-derived saccharomyces cerevisiae strain I017 or the microbial agent provided by the present invention can be widely used in the preparation of probiotic products with lipid-lowering effects.

[0079] The technical solution of the present invention will be further described below in conjunction with embodiments.

[0080] Example 1 Isolation and Identification of Deer-derived Yeast

[0081] 1.1 Materials:

[0082] 1.1.1 Test strains:

[0083] Sample strain: 1 yeast strain (Saccharomyces cerevisiae I017), isolated from the intestines of sika deer raised in Chifeng, Inner Mongolia.

[0084] 1.1.2 Reagents: as shown in Table 1-1.

[0085] Table 1-1 Test reagents:

[0086]

[0087] 2.1.3 Instruments: as shown in Table 1-2.

[0088] Table 1-2 Test instruments:

[0089]

[0090] 1.2 Methods:

[0091] 1.2.1 Sample collection: After the deer were killed, the contents of the small intestine were collected and cultured in YPD liquid medium for three replicates at room temperature to enrich the strains for subsequent strain isolation and purification.

[0092] 1.2.2 Isolation, culture and preservation:

[0093] In a sterile operating table, the enriched bacterial solution was subjected to 10 -1 ~10-6 Gradient dilution (100 µL culture solution added to 900 µL saline), 200 µL of diluted bacterial solution was spread on the YPD solid plate, which is used to culture yeast. Place it at 28 ℃ (for fungi) for constant temperature culture. After the colonies grow, use an inoculation loop to pick colonies of different forms and streak them on the plate in the clean bench. After the colonies are formed again, repeat the streaking operation until a single colony is formed on the plate, and then the strain purification operation is completed. The purified strains are inoculated into the corresponding liquid culture medium and continue to be cultured for staining and microscopy.

[0094] The purified strain was streaked onto a slant medium, and after colonies grew, they were freeze-dried and stored using 10% skim milk.

[0095] 1.2.3 Colony morphology and fungal staining microscopy:

[0096] After diluting the bacterial solution to a suitable concentration, spread it on a plate and observe the colony morphology after two days of culture. For fungal staining microscopy: first drop an appropriate amount of lactic acid phenol cotton blue staining solution on the slide, then use an inoculation loop to take a loop of fresh bacterial solution and put it in the staining solution. Then cover it with a coverslip and observe it under a microscope.

[0097] 1.2.4 Physiological and biochemical identification of fungi:

[0098] According to the Manual of Fungal Identification, the strains were subjected to physiological and biochemical tests on carbon source oxidation and carbon source utilization, and the strains were taxonomically identified based on the results.

[0099] 1.2.5 Growth characteristics and acid production characteristics of yeast I017:

[0100] The I017 culture solution that had been cultured overnight was subcultured at a 2% inoculation rate and cultured at 28°C and 160 rpm under constant temperature shaking conditions. Samples were taken at different time points after inoculation, and the absorbance of the culture solution at a wavelength of 600 nm was measured, and the pH value of the culture solution was also measured. The results of the measurement were used to draw the acid production curve and the growth curve.

[0101] 1.2.6 Homology analysis of fungal ITS rRNA sequences

[0102] Take an appropriate amount of fresh I017 bacterial liquid, extract its DNA according to the instructions, use fungal ITS rRNA universal primers to perform PCR reaction on the extracted DNA, and send the product to Wuhan Tianyi Huayu Gene Technology Co., Ltd. The sequencing results were processed for gene sequence alignment, and the phylogenetic tree was constructed using MEGA11 software to determine the taxonomic status of yeast I017.

[0103] 1.3 Results:

[0104] 1.3.1 Colony morphology and staining microscopy:

[0105] The colony is milky white, with a smooth surface, and grows well on the plate. The colony has convexities and a thick texture. Budding reproduction was observed under a microscope. Figure 1 .

[0106] Figure 1 The morphological characteristics of strain I017 provided in this embodiment. Figure 1 A in the middle is the colony morphology of strain I017; Figure 1 Middle B: Optical microscope photo; Figure 1 C in the middle is a scanning electron microscope observation photograph.

[0107] 1.3.2 Physiological and biochemical identification of fungi:

[0108] In the carbon source oxidation reaction, strain I017 can oxidize carbon sources such as acetic acid, formic acid, D-gluconic acid, dextrin, sucrose, D-trehalose, N-acetylglucosamine, D-galactose, and xylitol; the reaction results of strain I017 to propionic acid, succinic acid, methylsuccinate, L-aspartic acid, L-glutamic acid, L-proline, palatinose, turanose, salicin, glycerol, and Tween-80 are weakly positive; strain I017 cannot oxidize carbon sources such as D-raffinose, stachyose, α-D-glucose, inulin, cellobiose, gentiobiose, D-mannitol, D-sorbitol, and maltose.

[0109] In the carbon source utilization reaction, strain I017 can utilize fumaric acid, L-malic acid, bromosuccinic acid, dextrin, maltose, D-melezitose, D-melibiose, D-raffinose, L-sorbose, β-methyl D-glycoside, apricot glycoside, arbutin, ribitol, D-arabitol, xylitol, glycerol, Tween-80, L-arabinose, sucrose, D-glucosamine, L-rhamnose, D-xylose, D-trehalose, turanose, D-glucosamine, α-D-glucose, D-galactose, D-psicose, N-acetyl-L-glutamate + D-xylose, quinic acid + D-xylose, D-glucuronic acid + D-xylose, α- The carbon sources in D-galactose + D-xylose, D-melibiose + D-xylose, 1,2-propylene glycol + D-xylose; the reaction results of γ-aminobutyric acid, D-gluconic acid, salicin, D-mannitol, erythritol, D-ribose, methylsuccinate + D-xylose, dextrin + D-xylose, D-galactose + D-xylose, m-inositol + D-xylose, hydroxybutanol + D-xylose were weakly positive; strain I017 could not utilize the carbon sources in methylsuccinate, L-glutamic acid, inulin, cellobiose, gentiobiose, α-methyl D-glycoside, maltitol, D-sorbitol, palatinose, stachyose, and N-acetylglucosamine. Combined with the physiological and biochemical characteristics of the strain, it was preliminarily determined that the isolated fungus belonged to the genus Saccharomyces.

[0110] 1.3.3 Growth characteristics and acid production characteristics of strain I017:

[0111] Figure 2 The growth curve and acid production curve of strain I017 provided in this example.

[0112] like Figure 2 As shown in the figure, within 0-2 h after subculturing, the growth curve of I017 was relatively flat, the strain grew slowly, and was in the growth retardation stage. After 2 h, the growth rate of I017 increased significantly and entered the logarithmic growth phase; after 24 h of subculturing, the growth curve became flat and entered the stable phase. Similarly, within 12 h of subculturing, the pH value of the bacterial solution gradually decreased from the initial 6.45 to 5.8. After 12 h, the pH value of the bacterial solution remained at around 5.71. It can be seen that strain I017 can reach the maximum viable count and stable pH value within 24 h of subculturing.

[0113] 1.3.4 Homology analysis of fungal ITS rRNA sequences:

[0114] Figure 3 Phylogenetic tree of strain I017 provided in this example.

[0115] The ITS rRNA gene sequence of strain I017 was placed in the NCBI database for comparison, similar sequences were selected, their homology was compared, and a phylogenetic tree was constructed (see Figure 3 ), through phylogenetic analysis, it was identified that yeast I017 belongs to Saccharomyces cerevisiae and was named Saccharomyces cerevisiae I017.

[0116] Example 2 Study on the biological characteristics of Saccharomyces cerevisiae I017

[0117] 2.1 Materials:

[0118] 2.1.1 Reagents: as shown in Table 2-1.

[0119] Table 2-1 Test reagents:

[0120]

[0121] 2.1.2 Instruments: as shown in Table 2-2.

[0122] Table 2-2 Test instruments:

[0123]

[0124] 2.1.3 Test strains:

[0125] Sample strain: Saccharomyces cerevisiae I017, isolated from the intestine of sika deer raised in Chifeng, Inner Mongolia.

[0126] Pathogenic strains: Escherichia coli, Salmonella and Staphylococcus aureus were provided by the College of Agriculture of Chifeng University.

[0127] 2.2 Methods:

[0128] 2.2.1 Tolerance test of Saccharomyces cerevisiae I017 to artificial gastrointestinal fluid:

[0129] Prepare artificial gastric juice and artificial intestinal juice with reference to Part 4 of the 2015 edition of the Chinese Pharmacopoeia, and use them immediately after preparation.

[0130] Take an appropriate amount of fresh bacterial liquid, centrifuge it and discard the upper liquid, then add an equal amount of PBS and mix it again. Use a sterile microporous filter membrane to filter and sterilize the artificial gastric juice and artificial intestinal juice. Mix 9 volumes of artificial gastric juice and artificial intestinal juice with 1 volume of I017 bacterial suspension respectively, and culture at a constant temperature of 28 ℃. Use the plate counting method to calculate the number of viable bacteria at the beginning and after 3 hours of culture, so as to detect the activity of strain I017 in artificial gastric juice and artificial intestinal juice. The initial amount of viable bacteria is used as the control group, and the survival rate of strain I017 is calculated as follows:

[0131] Formula (3-1)

[0132] Where N0 is the number of viable bacteria at 0 h, and Nt is the number of viable bacteria at 3 h.

[0133] See Table 2-3 for test results.

[0134] Table 2-3 Number of viable bacteria of strain I017 in artificial stomach / intestinal fluid:

[0135]

[0136] As shown in Table 2-3, after 3 h of tolerance in artificial gastric juice, the survival rate of I017 was 96.75%, and the number of viable bacteria was about 9.12×10 5 CFU / mL; 3 h after inoculation in artificial intestinal fluid, the survival rate of the strain was 106.44%, and the number of viable bacteria was about 1.2×10 7 CFU / mL, indicating that Saccharomyces cerevisiae I017 can tolerate artificial gastric and intestinal juices well.

[0137] 2.2.2 Bile salt tolerance of Saccharomyces cerevisiae I017:

[0138] Take the activated I017 and inoculate it in a liquid culture medium containing 3% bile salt at a 2% inoculation rate, and culture it in a shaker at 28 ℃ and 160 revolutions per minute. Take samples at different time points after inoculation, measure the absorbance of the bacterial solution at a wavelength of 600 nm, and use the plate counting method to calculate the number of viable bacteria at the beginning and after 6 hours of culture. The initial number of viable bacteria is used as the control group, and the survival rate of strain I017 is calculated using the same calculation formula as formula 3-1.

[0139] The test results are shown in Tables 2-4 and Figure 4 .

[0140] Table 2-4 Survival rate of strain I017 in ox bile salt solution:

[0141]

[0142] Figure 4 This is a graph showing the bile salt tolerance results of Saccharomyces cerevisiae I017.

[0143] from Figure 4 It can be seen that Saccharomyces cerevisiae I017 continued to grow and reproduce in the culture medium with a bile salt concentration of 3 g / L. It grew slowly in the first 24 hours, gradually tolerated, and grew rapidly after 24 hours. As shown in Table 3-4, after 6 hours of tolerance, the survival rate of the strain was 115.33%, and the number of viable bacteria was about 4.17×10 6 CFU / mL, indicating that Saccharomyces cerevisiae I017 has a strong bile salt tolerance and its metabolites may contain bile salt hydrolase.

[0144] 2.2.3 Determination of surface hydrophobicity and self-aggregation of Saccharomyces cerevisiae I017:

[0145] The affinity of yeast for hydrocarbon compounds was used to evaluate the hydrophobicity of the strain. After 14 h of passage, I017 was centrifuged and washed twice with PBS. The absorbance of the bacterial solution at 600 nm was adjusted to about 0.25 for use. Take equal volumes of the test bacterial solution and xylene, mix them thoroughly, and incubate at 28 °C. After standing for 1 h and 2 h, take the water phase to measure the OD600 value (At), and the calculation formula is as follows:

[0146] Hydrophobicity (CSH) = [(A0-At) / A0] × 100% Formula (3-2)

[0147] Where: At is the absorbance at 1 h or 2 h; A0 is the absorbance at 0 h.

[0148] Figure 5 This is the test result of the surface hydrophobicity of Saccharomyces cerevisiae I017.

[0149] Depend on Figure 5The results of the hydrophobicity test showed that after treatment, the hydrophobicity of Saccharomyces cerevisiae I017 in the two time periods was 23.21% and 37.2%, respectively, with significant difference (P<0.05), indicating that the hydrophobicity of Saccharomyces cerevisiae I017 increased significantly with the increase of incubation time.

[0150] After 14 hours of passage, I017 was centrifuged, washed twice with PBS, and then mixed thoroughly with 2 times the volume of PBS. The OD600 value of the mixed bacterial solution was measured. After incubating 2 mL of the bacterial suspension for 2 hours and 4 hours, the absorbance of the supernatant was measured at 600 nm. The calculation formula is as follows:

[0151] Self-aggregation rate = [(A0-At) / A0] × 100% Formula (3-3)

[0152] Where: At is the absorbance at 2 h or 4 h; A0 is the absorbance at 0 h.

[0153] Figure 6 This is the test result of the self-aggregation rate of Saccharomyces cerevisiae I017.

[0154] Depend on Figure 6 It can be seen that after the I017 bacterial solution was left to stand for 2h and 4h, the self-aggregation rate was 89.83% and 95.38% respectively, and the difference between the two groups was significant (P<0.05). It can be seen that with the increase of standing time, the self-aggregation rate of Saccharomyces cerevisiae I017 increased significantly (P<0.05).

[0155] 2.2.4 Growth performance of Saccharomyces cerevisiae I017 in culture media with different pH values:

[0156] Adjust the pH value of YPD culture medium to 1, 2, 3, 4, 5, 6, 7, sterilize by high pressure at 121℃ for 15 min, and set aside. Take the activated I017 and inoculate it in YPD culture medium with initial pH of 1, 2, 3, 4, 5, 6, 7 at 2% inoculation amount, and culture it in a shaker at 28℃ and 160 revolutions per minute. Take samples at 5 time points after inoculation, and measure the absorbance of the bacterial solution at a wavelength of 600 nm. Repeat 3 times at each time point, and use the average value to draw the growth curve.

[0157] Figure 7 This is the growth curve of strain I017 under different acidic conditions.

[0158] like Figure 7It can be seen that the growth rate of strain I017 increases with the increase of the pH value of the culture solution. Saccharomyces cerevisiae I017 can hardly grow in YPD culture solution with initial pH values ​​of 1 and 2; the growth rate is significantly accelerated in liquid culture medium with initial pH values ​​of 3 to 7. Among them, when the pH value of the culture solution is 6-7, the strain grows fastest, the growth state is good, and the OD600 value of the strain in the stable period is the largest. This shows that Saccharomyces cerevisiae I017 has the best growth performance under the culture conditions of pH 6-7.

[0159] 2.2.5 Antibacterial test of fermentation supernatant of Saccharomyces cerevisiae I017:

[0160] The antibacterial properties of the strains were evaluated by the Oxford agar diffusion method. After 14 h of passage, the bacterial solution was centrifuged and the upper liquid was collected. The pathogenic bacteria were passaged and cultured overnight, and the bacterial solution concentration was adjusted to 10 7 CFU / mL, take appropriate amount of different pathogenic bacteria liquid and spread evenly on the plate. After the liquid is fully absorbed, place 3 Oxford cups and arrange them in the shape of a finished product. Add 200μL of fermentation supernatant to the Oxford cup, and use the new liquid culture medium as a negative control. After overnight culture in a 28 ℃ constant temperature incubator, observe whether an inhibition zone is formed, and use a vernier caliper to accurately measure the diameter of the inhibition zone.

[0161] The test results are shown in Tables 2-5 and Figure 8 .

[0162] Figure 8 This is a graph showing the inhibitory effect of strain I017 on Staphylococcus aureus. Figure 8 A in the middle is the inhibitory effect of the fermentation supernatant of strain I017 on Staphylococcus aureus; Figure 8 B is the control using YPD culture medium.

[0163] The in vitro antibacterial ability of Saccharomyces cerevisiae I017 was determined by the Oxford cup agar diffusion method. The results are shown in Tables 2-5 and Figure 8 As shown. Taking YPD liquid medium as negative control, the fermentation supernatant of strain I017 had a good inhibitory effect on Staphylococcus aureus, with an inhibition zone diameter of 13.50±0.02mm, but had no inhibitory effect on Escherichia coli and Salmonella.

[0164] Table 2-5 Antibacterial test results:

[0165]

[0166] Note: The inner diameter of the Oxford cup is 6.0 mm, and the outer diameter is 8.0 mm. “-” means the diameter of the inhibition zone is less than 8 mm, indicating no antibacterial activity.

[0167] 2.2.6 Drug sensitivity test:

[0168] The Rosco disc diffusion method is used. During the preparation of the inoculum, accurate control of the concentration is crucial. Too high an inoculum concentration will make it difficult to interpret the inhibition zone of pyrrole / imidazoles, resulting in false negative results.

[0169] After activation, most fungi need to adjust the concentration of the inoculum to 5×10 5 CFU / mL; before coating, the plate was dried for 20-25 minutes. For a 9 cm plate, 0.5 ml of inoculum was aspirated, poured on the surface of the plate, coated evenly, and excess liquid was aspirated with a pipette. Then, the plate was left to dry for 10 minutes, and the tablets were applied, with 3 replicates for each tablet. Overnight culture was performed, and the diameter of the inhibition zone was measured, and compared with the CLSI standard to determine the sensitivity of Saccharomyces cerevisiae I017 to the drug.

[0170] The test results are shown in Table 2-6.

[0171] Table 2-6 Antibiotic sensitivity test results:

[0172]

[0173] Note: R: resistant; I: intermediate; S: sensitive; “−” means no inhibition zone.

[0174] As shown in Table 2-6, Saccharomyces cerevisiae I017 is sensitive to voriconazole, ketoconazole, fluconazole and itraconazole. Among them, the diameter of the drug sensitivity zone of voriconazole is the largest, which is 30.33±0.58 mm; it is moderately sensitive to amphotericin B, and its inhibition zone diameter is 13.50±0.50 mm. This shows that Saccharomyces cerevisiae I017 is sensitive to most commonly used antifungal drugs and has good safety.

[0175] 2.2.7 Enzyme production capacity of Saccharomyces cerevisiae I017:

[0176] Amylase screening medium: YPD medium with 0.2% soluble starch added;

[0177] The content of the culture medium for screening cellulase is as follows (g / L): CMC-Na, 10 g; yeast powder, 0.6 g; K2HPO4, 2 g; KH2PO4, 7 g; MgSO4·7H2O, 0.1 g; (NH4)2SO4, 1 g; agar powder, 20 g; The following is the content of the culture medium for screening protease (g / L): glucose, 5 g; casein, 10 g; peptone, 5 g; KH2PO4, 1 g; NaCl, 5 g; agar powder, 20 g. Autoclave at 121℃ for 15 min.

[0178] Place sterile filter paper (3-4 mm in diameter) evenly in each screening plate, with 3 filter paper in each plate, and drop 10 μL of bacterial solution (10 7 ~10 8 CFU / mL), cultured at 28 ℃, and observed the colony growth every 16 h. After obvious colonies grew, the amylase screening plate was stained by iodine fumigation method to observe whether there was a hydrolysis zone around the colony; the plate for detecting cellulase production was added with an appropriate amount of 0.2% Congo red solution for color development, and the reaction time was 30 minutes. The Congo red solution was poured out, and then 3 mL of 1 mol / L NaCl solution was added. After elution for 15 min, the washing solution was poured out to check whether a hydrolysis transparent zone was formed; for the protease screening plate, directly observe whether there was a hydrolysis transparent zone, and record the diameter of the hydrolysis zone.

[0179] Fig. 9 This is the amylase hydrolysis circle produced by Saccharomyces cerevisiae I017.

[0180] Table 2-7 Enzyme production results of strain I017:

[0181]

[0182] Note: “−” indicates no hydrolysis cycle.

[0183] According to Table 2-7, Fig. 9 The results showed that Saccharomyces cerevisiae I017 had a strong ability to hydrolyze starch, and its hydrolysis zone size was 28.5±0.2 mm. However, there was no transparent hydrolysis zone on the cellulase screening medium and casein medium, indicating that the strain may not produce cellulase and protease.

[0184] 2.2.8 DPPH radical scavenging ability of Saccharomyces cerevisiae I017

[0185] Centrifuge the I017 bacterial suspension 14 h after subculturing, wash the bacteria twice with PBS, and then add an equal volume of PBS to mix thoroughly. Take an equal volume of bacterial suspension and 0.20 mmol / L DPPH anhydrous ethanol solution, and oscillate for 1 min to achieve thorough mixing. Incubate in a light-proof incubator for 30 min, centrifuge the reaction solution, and measure the absorbance of the supernatant at 517 nm. The clearance rate is calculated as follows:

[0186] DPPH free radical scavenging rate (%) = [1-(A1-A2) / A0] × 100 Formula (3-4)

[0187] Where: A0 is the absorbance value measured when an equal volume of PBS is used instead of the sample; A1 is the absorbance of the sample group; A2 is the absorbance measured when an equal volume of anhydrous ethanol is used instead of the DPPH ethanol solution.

[0188] The in vitro antioxidant capacity of the strain was reflected by measuring the scavenging ability of Saccharomyces cerevisiae I017 on DPPH. According to the measurement results (see Table 2-8), the DPPH free radical scavenging rate of I017 was 58.96%, indicating that Saccharomyces cerevisiae I017 has a good antioxidant effect.

[0189] Table 2-8 DPPH free radical scavenging rate of strain I017

[0190]

[0191] 2.2.9 In vitro bile salt hydrolase assay of Saccharomyces cerevisiae I017

[0192] Add 3 g / L sodium deoxytaurocholate, 2 g / L sodium thioglycolate, 0.37 g / L CaCl2 and 15 g / L agar to the freshly prepared liquid culture medium, sterilize at 121℃ for 15 min, pour into a sterile plate, and evenly place sterile filter paper pieces in the plate after solidification, drop 10 μL of fresh bacterial solution on each filter paper piece, and culture for 72 h. If white precipitate appears around the filter paper piece, it indicates that the test strain can produce bile salt hydrolase.

[0193] Fig.10 This is a comparison chart of the bile salt hydrolase activity of strain I017. Fig.10 A in the middle is the identification culture medium; Fig.10 B is the YPD solid medium control group.

[0194] Bile salt hydrolase activity has become an important indicator for in vitro screening of cholesterol-lowering strains. Fig.10 As shown in the figure, after culturing at 28°C for 48 hours, there was no white precipitate around the filter paper of the control group and the strain I017, indicating that Saccharomyces cerevisiae I017 may not produce bile salt hydrolase and cannot hydrolyze the bound bile salt into free bile acid, so that no free bile acid combines with CaCl2 in the culture medium to produce white precipitate.

[0195] 2.2.10 Qualitative determination of lipase from Saccharomyces cerevisiae I017

[0196] Preparation of screening medium, neutral red medium with sunflower oil as the sole carbon source: on the basis of YPD medium, add 5.0 g / L sunflower oil instead of glucose, add 1 mL of 1.6% neutral red aqueous solution, adjust the pH to 7.0, and sterilize at 120 ℃ for 30 minutes.

[0197] The strain is streaked on the screening medium plate for 72 hours, and the color of the streaked part is observed to see if it turns red. If it turns red, it proves that the strain has the function of producing lipase, which can decompose oil into glycerol and fatty acids. Fatty acids can reduce the pH of the culture medium. Neutral red, as an acid-base indicator, is red under acidic conditions and will dye the bacteria red.

[0198] Fig.11 This is a graph showing the growth of strain I017 on neutral red medium.

[0199] After the isolated and purified strain I017 was streaked on a neutral red medium plate, the growth rate was slow, but the colonies in the streaked area turned red ( Fig.11 ), indicating that strain I017 may produce lipase, decompose the vegetable oil in the culture medium, generate fatty acids, reduce pH, and turn red under the action of 1.6% neutral red aqueous solution.

[0200] 2.2.11 Phosphorus-sulfur-iron colorimetric method for in vitro determination of cholesterol-lowering ability of Saccharomyces cerevisiae I017

[0201] Verify the preparation of the culture medium, YPD-CHOL liquid culture medium: Add cholesterol 1 g / L, Tween-80 20 mL / L, and ox bile salt 3 g / L to the YPD liquid culture medium. Place the cholesterol in Tween-80, heat it to boil, and slowly pour it into the culture medium while it is hot after it is fully dissolved. It will be in the state of micellar solution. The color of this culture medium is opaque light yellow. After sterilizing the prepared culture medium at 121 ℃ for 20 min, mix it while it is hot to completely dissolve the colloid, and place it at room temperature to cool naturally.

[0202] Phosphorus-sulfur-iron colorimetric method: add 9 mL of methanol and 0.1 mL of supernatant to a centrifuge tube, centrifuge at 8000 r / min for 5 min; take 2 mL of supernatant and add it to a clean test tube, then slowly add 2 mL of prepared phosphorus-sulfur-iron reagent along the tube wall, gently shake evenly, and cool at room temperature for 30 min; after the generated color stabilizes, use a double-beam UV-visible spectrophotometer to perform colorimetry at a wavelength of 550 nm and record the results. (The reaction solution of 2 mL of methanol and 2 mL of phosphorus-sulfur-iron reagent is used as blank for zero adjustment)

[0203] Take 5% of the secondary activated bacterial solution and inoculate it into YPD-CHOL medium containing 1 g / L cholesterol. After constant temperature shaking culture at 28 °C and 160 r / min for 48 h, take 5 mL of bacterial solution, centrifuge at 8000 r / min for 10 min, and take the supernatant to measure the absorbance A at a wavelength of 550 nm according to the phosphorus-sulfur-iron colorimetric method. Calculate the cholesterol removal rate according to the formula:

[0204] Cholesterol removal rate (%) = (A0-A1) / A0×100% Formula (3-5)

[0205] Where: A0 is the OD value of the uninoculated YPD-CHOL medium at 550 nm, and A1 is the OD value of the culture solution after the strain fermentation at 550 nm.

[0206] Table 2-9 In vitro cholesterol removal rate of strain I017:

[0207]

[0208] The in vitro cholesterol-lowering experiment is an important criterion for preliminarily determining whether a strain has the potential to lower lipids. In this experiment, the in vitro cholesterol removal rate of strain I017 was determined by the phosphorus-sulfur-iron colorimetric method to reflect the cholesterol-lowering ability of the strain. The experimental results are shown in Table 2-9. After 48 hours of cultivation, the in vitro cholesterol removal rate of strain I017 was 19.23%. This shows that Saccharomyces cerevisiae I017 has a certain cholesterol-lowering effect.

[0209] 2.2.12 Determination of triglyceride lowering function of Saccharomyces cerevisiae I017:

[0210] Triglyceride culture medium: 2% polyvinyl alcohol aqueous solution was mixed with sunflower oil in a volume ratio of 3:1, and then treated with ultrasound (control parameters: 5 s per ultrasound, 5 s interval, 70 times in total) and mixed evenly to make sunflower oil emulsion as the source of triglycerides. The sunflower oil emulsion was added to the YPD culture medium at a ratio of 4%, and sterilized by high pressure steam at 115 °C for 30 min.

[0211] Saccharomyces cerevisiae I017 was inoculated into triglyceride medium, and samples were taken after one day of shaking culture. The operation method and steps were carried out according to the instructions of the triglyceride kit, and the remaining triglyceride content was determined. The uninoculated triglyceride medium was used as the control group, with 3 replicates in each group, and the calculation formula was as follows:

[0212] TG removal rate (%) = (C0-C1) / C0×100% Formula (3-6)

[0213] Where: C0 is the total TG content, mg / mL; C1 is the remaining TG content, mg / mL.

[0214] The test results are shown in Table 2-10.

[0215] Table 2-10 Degradation ability of strain I017 on triglycerides:

[0216]

[0217] The in vitro triglyceride reduction experiment can also preliminarily determine whether the strain has the potential to reduce blood lipids. As shown in Table 2-10, the triglyceride removal rate of Saccharomyces cerevisiae I017 is as high as 50.31%, indicating that Saccharomyces cerevisiae I017 has a good in vitro degradation ability for triglycerides.

[0218] 2.2.13 Data Processing

[0219] The application used for data analysis was SPSS 26.0, the statistical method was one-way analysis of variance, and the results were expressed as mean ± standard deviation; the mapping software used was Origin 2021. Different lowercase letters in the figure indicate significant differences (P<0.05).

[0220] It should be noted that studies have shown that the probiotic effects of brewer's yeast on animals include: it is beneficial to the digestion and absorption of nutrients by animals, promotes the growth of animals, increases the average daily weight gain, and can also participate in immune regulation and enhance the immunity of animals. The basic requirements for strains to work in the intestines of animals are: they can survive in large quantities in intestinal fluid, gastric juice, bile salts, and acidic environments, and can be well colonized and proliferated in the intestines. In addition, for host animals, it is also necessary to ensure that the strains are non-resistant and have no toxic side effects. Animal diets are rich in grains and have high energy, which may lead to insufficient digestion and absorption of nutrients by animals, or cause hyperlipidemia in animals, which is not conducive to the health of animals. Therefore, it is also necessary to screen probiotics with the function of producing digestive enzymes, which helps animals digest and absorb nutrients. After the above screening, yeasts with probiotic potential are developed to provide material materials and scientific data for the research and development of probiotic yeasts.

[0221] It can be seen from the above-mentioned Test Example 2 of the present application that brewer's yeast I017 has a strong tolerance to artificial gastric juice, can grow and reproduce in artificial intestinal juice, can tolerate the highest bile salt concentration in the animal intestine, and has good acid resistance. It is a yeast with strong stress resistance, which provides a theoretical basis for the brewer's yeast to be colonized in the animal digestive tract as a probiotic preparation and exert a probiotic effect.

[0222] At the same time, studies have found that the strain's adhesion to cells is significantly correlated with its hydrophobicity and self-aggregation rate. The self-aggregation of the present application's Saccharomyces cerevisiae I017 is strong, reaching 89.83% after 2 hours; while the hydrophobicity is relatively weak, with a hydrophobicity of 37.2% after 2 hours, indicating that Saccharomyces cerevisiae I017 may have good cell adhesion properties. With the increase of incubation time, the self-aggregation rate and hydrophobicity of strain I017 increased significantly, indicating that the adhesion of the Saccharomyces cerevisiae may increase with time. In addition, Saccharomyces cerevisiae I017 can secrete amylase and lipase in vitro; it has a high in vitro degradation rate of triglycerides, and can also remove part of cholesterol in vitro, and has the potential to lower blood lipids.

[0223] Example 3

[0224] In the above Example 2, Saccharomyces cerevisiae I017 was identified and its in vitro biological characteristics such as stress resistance, drug sensitivity, antibacterial effect, adhesion performance and enzyme production capacity were evaluated. In addition, the safety of the strain is a basic requirement for its promotion and application. The following experiment used mice as an animal model and continuously gavaged them with I017 bacterial solution for 15 days. We evaluated the safety of the bacteria in vivo by observing the changes in mouse weight, organ health, intestinal health and measuring serum biochemical indicators.

[0225] 3.1 Materials:

[0226] 3.1.1 Test strains

[0227] Sample strain: Saccharomyces cerevisiae I017 ( Saccharomyces cerevisiae ), isolated from the intestine of sika deer raised in Chifeng, Inner Mongolia.

[0228] Fermentation medium: YPD liquid medium. Main ingredients: 10g yeast extract powder, 20g peptone, 20g glucose, 1000mL sterile water.

[0229] 3.1.2 Experimental animals

[0230] Twelve C57 mice, 4 weeks old, male, and weighing 20-24 g, were purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0231] 3.2 Methods

[0232] 3.2.1 Preparation of I017 bacterial solution

[0233] The I017 bacterial solution was subcultured at a 2% inoculum volume and cultured in a constant temperature shaker for about 16 h to allow the bacterial solution concentration to reach 10 7 CFU / mL.

[0234] 3.2.2 Feeding plan

[0235] Twelve 4-week-old male C57 mice were selected for strain safety evaluation. After 5 days of pre-feeding, the mice were randomly divided into 2 groups, 6 in each group, respectively, the control group and the experimental group. The experimental period was 15 days. The mice in the experimental group were gavaged with 10 mL / Kg of 10% 10% 10% 10% 10% 10% 10% 10% 10% 7 CFU / mL of I017 bacterial solution; the control group mice were gavaged with an equal amount of normal saline every day. During the experiment, the mice were free to drink water and eat on their own.

[0236] 3.2.3 Mouse body weight measurement

[0237] During the experimental period, the body weights of the two groups of mice were recorded on the 1st day, 3rd day, 5th day, 7th day, 9th day, 11th day, 13th day, and 15th day, and the average body weights of the two groups on the same day were calculated, and the weight change graphs of the two groups of mice were drawn. Before weighing, the mice were fasted overnight (about 12 hours, and fasting but not water deprivation).

[0238] Fig.12 This is a graph showing the initial and final weight effects on mice. Fig.12 Con: control group; JM: experimental group; ns: no statistical difference.

[0239] Depend on Fig.12 It can be seen that there was no significant difference in the initial body weight of the two groups of mice. After continuous intragastric administration of I017 bacterial solution for 15 days, the body weight of mice in both the experimental group and the control group increased (see Fig.12 There was no significant difference in the final body weight between the two groups of mice.

[0240] Fig.13 This is a growth curve diagram of mice provided in this example.

[0241] Fig.14 The final body shape of the mouse provided in this example.

[0242] Probiotics should not only have excellent biological properties, but also ensure their safety and have no adverse effects on the animal body. In this study, there were no deaths or abnormalities in the mice that were administered with bacterial solution; after dissection, it was found that the organs had good morphology, normal color, size and properties, and no lesions. Overall, the weight increase trend of mice in the experimental group and the control group was similar, and there was no significant difference in the final weight. This shows that Saccharomyces cerevisiae I017 has no adverse effects on the growth and development of mice.

[0243] 3.2.4 Calculation of organ index

[0244] After the 15-day test period, the mice were killed by dislocating the neck. Then the mice were dissected: the chest and abdominal skin of the mice were disinfected, the chest and abdominal cavities were opened, and the internal organs were observed for lesions.

[0245] The liver, spleen, kidney and intestine of the mice were removed and rinsed with sterile saline and dried with filter paper. The appearance of the organs of the two groups of mice was compared and their weights were recorded. The length of the colon was also measured. The calculation formula is as follows:

[0246] Organ index (%) = weight of each organ (g) / weight of mouse (g) × 100% Formula (4-1)

[0247] Fig.15 The liver morphology, weight and liver index of mice provided in this example;

[0248] Fig.16 The mouse spleen morphology, weight and spleen index diagram provided in this example;

[0249] Fig.17 The mouse kidney morphology, weight and kidney index diagram provided in this example;

[0250] Fig.18 Figure 3 shows the intestinal morphology, weight and colon length of mice provided in this example;

[0251] like Figures 15 to 18 As shown in the figure, after feeding mice with Saccharomyces cerevisiae I017 liquid for 15 days, there was no significant difference in the morphology of the organs of the mice in the experimental group and the control group. Their color, size and properties were normal, and there was no pathological phenomenon. There was no statistical difference in the weight of the mouse organs (including liver, spleen, and kidney) between the two groups, and there was no significant difference between the organ indexes. Similarly, there was no significant difference in the intestinal weight and colon length of the two groups of mice. The results show that strain I017 is safe in mice, and it can be preliminarily considered that Saccharomyces cerevisiae I017 is a safe strain.

[0252] The organ index can reflect the growth and development of mice and their immune function. As the age of mice increases, the organ index usually remains stable. However, if mice ingest toxic substances, their organ index will also change accordingly. In this embodiment, there was no significant difference in the organ index between the experimental group and the control group, and there was no significant difference in the colon length between the two groups (P>0.05), indicating that Saccharomyces cerevisiae I017 is safe for mice and does not affect the body immunity and colon function of mice.

[0253] 3.2.5 HE staining to observe the tissue structure of jejunum and colon

[0254] After the mice were killed, the middle part of the jejunum and the middle part of the colon were selected, washed with PBS, dried, and fixed in 4% paraformaldehyde solution. Conventional paraffin embedding, sectioning, and HE staining were performed, and the tissue structure was observed under a microscope.

[0255] Fig.19 This is the HE staining result of mouse jejunum tissue provided in this example. Fig.19 HE staining of mouse jejunum tissue is a (100×) magnified image.

[0256] Fig. 20 This is the HE staining result of mouse colon tissue provided in this example. Fig. 20 HE staining of mouse colon tissue (100×) magnified image.

[0257] Depend on Fig.19 , Fig. 20It can be seen that the jejunal tissue structure of the experimental group and the control group mice is similar, with intact villi, tightly arranged, regular morphology, and no histological lesions; Fig. 20 It can be seen that there is no significant difference in the colon tissue structure between the experimental group and the control group, the epithelium is intact, the goblet cells are abundant, and there is no inflammatory cell infiltration. The results show that Saccharomyces cerevisiae I017 does not cause damage to the jejunum and colon of mice and does not affect intestinal function.

[0258] In the animal intestine, the jejunum is mainly responsible for digestion and absorption of nutrients, while the colon is mainly responsible for the absorption of water and electrolytes and the formation of feces. Together, they constitute an important link in the digestive system, ensuring that the animal body can obtain the required nutrients and excrete metabolic waste. When the intestine is damaged, the jejunal villi atrophy and shorten, the crypt depth increases, and inflammatory cell infiltration occurs; the colon tissue shows obvious damage, such as inner mucosal damage, mucosal ulcers, mucosal congestion, obvious inflammatory cell infiltration, obvious goblet cell loss, crypt integrity destruction, muscular edema, and histological scores are significantly increased (P<0.001). In this embodiment, after mice were gavaged with Saccharomyces cerevisiae I017 bacterial solution for 15 days, the mouse jejunum and colon tissue structure were intact and without lesions, indicating that the bacteria do not cause damage to the intestine and will not affect the digestion, absorption and excretion function of the mouse intestine.

[0259] 3.2.6 ALT and AST levels in mouse serum

[0260] Eyeball blood was collected from the two groups of mice, and the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the mouse serum were detected using a kit.

[0261] Fig.21 This is a graph showing the levels of ALT and AST in mouse serum.

[0262] The levels of ALT and AST in the serum of the two groups of mice were detected using a kit. Fig.21 It can be seen that there was no statistical difference in the serum ALT and AST levels of mice in the JM group compared with the control group (P>0.05). The results showed that feeding I017 bacterial liquid had no effect on the serum ALT and AST levels of mice.

[0263] Transaminase is an important clinical indicator of liver function, and liver damage can be examined by detecting changes in ALT and AST in serum. When the animal liver is damaged, the transaminase AST and ALT in the serum will increase significantly. In this embodiment, compared with the control group, there was no significant change in the transaminase AST and ALT in the serum of the experimental group of mice, indicating that Saccharomyces cerevisiae I017 does not cause liver damage and does not affect liver function.

[0264] 3.2.7 Data processing: GraphPad Prism 8.3.0 was used to draw graphs in this experiment. ns means no statistical difference.

[0265] In summary, it was concluded from Example 3 of the present application that Saccharomyces cerevisiae I017 is safe for mice and does not affect the immunity, intestinal function and overall health of mice.

[0266] Example 4

[0267] The present application relates to the effects of the deer-derived Saccharomyces cerevisiae strain I017 on the feed intake and antler weight of sika deer.

[0268] Purpose:

[0269] The effect of adding deer-derived brewer's yeast to the diet on feed intake and antler production was studied.

[0270] Experimental methods:

[0271] Thirty-two healthy sika deer (125.20±5.06) kg of the same age were selected and randomly divided into four groups, with 8 deer in each group.

[0272] 1. The control group (N group) was fed with a basic diet;

[0273] 2. Experimental group 1: Deer-derived Saccharomyces cerevisiae strain I017 group;

[0274] 3. Experimental group 2: commercially available Candida group;

[0275] 4. Experimental group 3: commercially available Saccharomyces cerevisiae strain group;

[0276] 5. Experimental group 4: Deer-sourced Pichia kudriavzevii CFCFC010 group.

[0277] Note: The above-mentioned Luyuan Kudriazevich Pichia yeast CFCFC010 was isolated by our unit and can be sold to the outside.

[0278] The experimental group was fed 5 mL (live bacteria count of about 1.03×10 9 CFU / mL, the number of viable bacteria in each supplementation group reached 10 9 CFU / mL) fresh bacterial liquid. The pre-test period was 7 days, and the average test period was 45 days. The feed amount and the amount of leftover feed were weighed every day to calculate the daily feed intake of each deer. When the second antler growth was completed, the antler weight was weighed.

[0279] Statistics:

[0280] The data were sorted using Excel 2021 and tested for normal distribution. One-way ANOVA in SAS 9.0 software was used to test the significance of the difference. The test results were expressed as mean ± standard deviation, and P < 0.05 indicated a significant difference.

[0281] The experimental results are shown in the following table:

[0282]

[0283] Note: Data in the same row with different letters on the shoulders indicate significant differences (P<0.05); data with the same letters on the shoulders or no letters on the shoulders indicate no significant differences (P>0.05).

[0284] As can be seen from the table, the average daily feed intake of deer in each group was not significantly different (p>0.05), but the antler production of each group was significantly different (p<0.05);

[0285] The group with added deer-derived brewer's yeast I017 (experimental group 1) had an average antler yield of 3.16 kg (1.66~5.27 kg); the group with commercially available Candida albicans (experimental group 2) had an average antler yield of 2.02 kg (1.61~3.76 kg); the group with commercially available brewer's yeast (experimental group 3) had an average antler yield of 2.11 kg (1.32~4.01 kg); the group with deer-derived Pichia kudriavzevii CFCFC010 (experimental group 4) had an average antler yield of 2.08 kg (1.10~4.20 kg); and the control group had an average antler yield of 2.75 kg (1.56~4.71 kg).

[0286] Experimental conclusion:

[0287] The addition of deer-derived brewer's yeast to the diet had no significant effect on the feed intake of sika deer, but it could significantly increase the weight of antlers. The weight of antlers increased by 0.41kg compared with the control group, 1.14kg compared with the commercial Candida species, 1.08kg compared with the deer-derived Pichia kudriazevii CFCFC010 group, and 1.05kg compared with the commercial brewer's yeast group. Comprehensive analysis shows that the deer-derived brewer's yeast strain I017 can significantly increase the weight gain effect of sika deer antlers, while other yeast solutions, when fed, will seriously affect the weight gain effect of sika deer antlers compared with the control group. The specific related mechanisms are still under further study.

[0288] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A deer-derived Saccharomyces cerevisiae strain I017, characterized in that: The deposit number is CCTCC NO: M2024600.

2. A microbial agent, characterized in that: The microbial agent comprises the deer-derived saccharomyces cerevisiae strain I017 as described in claim 1 and auxiliary materials.

3. The microbial agent according to claim 2, characterized in that: The microbial agent is the fermentation liquid of deer-derived saccharomyces cerevisiae strain I017.

4. The microbial agent according to claim 3, characterized in that: The live bacteria concentration of the deer-derived saccharomyces cerevisiae strain I017 in the fermentation broth is 10 5 ~10 9 CFU / mL.

5. The microbial agent according to claim 4, characterized in that: The live bacteria concentration of the deer-derived saccharomyces cerevisiae strain I017 in the fermentation broth is 10 7 CFU / mL.

6. Use of the deer-derived Saccharomyces cerevisiae strain I017 according to claim 1 or the microbial agent according to any one of claims 2 to 5 in the preparation of a feeding probiotic product for promoting the growth of sika deer antlers.

7. A feeding probiotic product for promoting the growth of sika deer antlers, characterized in that: The feeding probiotic product is a fermented bacterial liquid of the deer-derived saccharomyces cerevisiae strain I017, and the deposit number of the deer-derived saccharomyces cerevisiae strain I017 is CCTCCNO: M2024600; The live bacteria concentration of strain I017 in the fermentation broth was 10 5 ~10 9 CFU / mL.

8. The probiotic product for feeding to promote the growth of sika deer antlers according to claim 7, characterized in that: The feeding probiotic product is a fermented bacterial liquid of deer-derived Saccharomyces cerevisiae strain I017; The live bacteria concentration of strain I017 in the fermentation broth was 10 7 CFU / mL.

9. Use of the deer-derived Saccharomyces cerevisiae strain I017 according to claim 1 or the microbial agent according to any one of claims 2 to 5 in the preparation of a feed additive or health product for regulating the intestinal flora structure of sika deer.

10. Use of the deer-derived Saccharomyces cerevisiae strain I017 according to claim 1 or the microbial agent according to any one of claims 2 to 5 in the preparation of a probiotic product with lipid-lowering effect.